triamterden

Triamterden appears to be a variant spelling of triamterene, a potassium-sparing diuretic used in the management of hypertension and edema. Triamterene is commonly prescribed alone or in fixed combinations with thiazide diuretics to counteract thiazide-induced potassium loss while promoting natriuresis.

The drug acts on the distal nephron, inhibiting epithelial sodium channels (ENaC) in the cortical collecting duct. By reducing sodium reabsorption at this site, triamterene decreases the electrochemical gradient for potassium secretion and therefore helps conserve serum potassium. Its diuretic effect is generally milder than that of loop or thiazide diuretics.

Adverse effects include the risk of hyperkalemia, particularly in patients with renal impairment or when used with other agents that raise potassium (such as ACE inhibitors, angiotensin receptor blockers, certain potassium supplements, or potassium-sparing medications). Other reported effects include nausea, dizziness, rash, and, rarely, kidney stones or impaired renal function. Laboratory monitoring of serum electrolytes and renal function is recommended during therapy.

Triamterene is available in combination formulations (notably with hydrochlorothiazide) under several brand names and in some regions as a single-agent preparation. Use is guided by clinical judgment balancing diuretic benefit with the risk of electrolyte disturbances and interactions.